This, in combination with the established role of BDNF-Met in cognitive impairment in AD, clearly shows that there is a need for new treatments for AD that improve memory using a different mechanism of action than the anti-amyloid antibodies. This evidence concerns the gene BDNF and Alzheimer disease.